Recent advancements for the evaluation of anti-viral activities of natural products

New Biotechnology

Volumn 25, Issue 5, 2009, Pages 347-368

  Chattopadhyay, Debprasad ^a   Sarkar, Mamta Chawla ^b   Chatterjee, Tapan ^c   Sharma Dey, Rakhi ^b   Bag, Paromita ^a   Chakraborti, Sekhar ^b   Khan, Mahmud Tareq Hassan ^d  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c JADAVPUR UNIVERSITY   (India)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-VIRAL DRUGS; ANTIVIRAL AGENTS; DRUG DISCOVERY PROCESS; ENZYME INHIBITORS; IN-VITRO; NATURAL PRODUCTS; NUCLEOSIDE ANALOGUES; NUCLEOTIDE ANALOGUES; PHYTOCHEMICALS; PLANT EXTRACT; POTENTIAL SOURCES; THYMIDINE KINASE; TRADITIONAL CHINESE MEDICINE;

ACICLOVIR; ANTIVIRUS AGENT; LAMIVUDINE; N(G) NITROARGININE METHYL ESTER; NATURAL PRODUCT; NITRIC OXIDE SYNTHASE INHIBITOR; VIRUS DNA;

ANTIVIRAL ACTIVITY; AYURVEDA; AZADIRACHTA INDICA; BAGG ALBINO MOUSE; BOEHMERIA NIVEA; CARISSA EDULIS; CHINESE MEDICINE; COTTON RAT; CYTOPATHOGENIC EFFECT; DNA SYNTHESIS; DRUG SCREENING; DUCKLING; ENZYME LINKED IMMUNOSORBENT ASSAY; FERRET; GERANIUM SANGUINEUM; GUAZUMA ULMIFOLIA; GUINEA PIG; HEPATITIS B VIRUS; HERPES VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO SELECTION; IN VIVO STUDY; LD 50; LIVER; LYCORIS RADIATE; MEDICINAL PLANT; NONHUMAN; OLIVE TREE; PHYLLANTHUS AMARUS; PHYLLANTHUS URINARIA; POLYGONUM CUSPIDATUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RABBIT; RABIES VIRUS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SAMBUCUS; SAXIFRAGA MELANOCENTRA; SOUTHERN BLOTTING; SOYBEAN; SPINAL GANGLION; TOXICITY TESTING; TRANSGENIC MOUSE; TRICHILIA GLABRA; VAGINITIS; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; DRUG EVALUATION; DRUGS, CHINESE HERBAL; HUMANS; PLANT EXTRACTS; RESEARCH;

EID: 67349220415     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbt.2009.03.007     Document Type: Review

References (128)

1. Chattopadhyay D., et al. Viruses, the acellular parasites of cellular hosts: biology and pathology with special reference to HIV. Ind. J. STD AIDS 20 (1999) 54-60
2. Wagner E.K., and Hewlett MJ. Basic Virology. 1st ed. (1999), Blackwell Science, Inc. 1-4051-0346-9
3. Chattopadhyay D., and Bhattacharya S.K. Ethnopharmacology: a new search engine for the development of antivirals from naturaceuticals. In: Eddouks M. (Ed). Handbook of Ethnopharmacology (2008), Research Signpost Publication 129-197 Chapter 5
4. Chattopadhyay D., and Naik T.N. Antivirals of ethnomedicinal origin: structure-activity relationship and scope. Mini Rev. Med. Chem. 7 (2007) 275-301 Review
5. Khan M.T.H., et al. Extracts and molecules from medicinal plants against herpes simplex viruses. Antivir. Res. 67 (2005) 107-119 and references cited therein
6. Chattopadhyay D. Ethnomedicinal antivirals: scope and opportunity. In: Ahmad I., Aquil F., and Owais M. (Eds). Modern Phytomedicine: Turning Medicinal Plants into Drugs (2006), Wiley-VCH 313-338 Chapter 15
7. Naithani R., et al. Antiviral activity of phytochemicals: a comprehensive review. Mini Rev. Med. Chem. 8 (2008) 1106-1133
8. Christopher M.E., and Wong J.P. Recent developments in delivery of nucleic acid-based antiviral agents. Curr. Pharm. Des. 12 (2006) 1995-2006
9. Chattopadhyay D., and Khan M.T.H. Ethnomedicines and ethnomedicinal phytophores against herpesviruses. Biotechnol. Annu. Rev. 14 (2008) 297-348
10. Hudson J.B. Antiviral Compounds from Plants (1990), CRC Press pp. 119-131
11. Venkateswaran P.S., et al. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 274-278
12. Thyagarajan S.P., et al. Phyllanthus amarus and hepatitis B. Lancet 336 8720 (1990) 949-950
13. Thyagarajan S.P., et al. Phyllanthus amarus and hepatitis B. Lancet 335 8705 (1990) 1600-1601
14. Chantrill B.H., et al. The action of plant extracts on a bacteriophage of Pseudomonas pyocyanea and on influenza A virus. J. Gen. Microbiol. 6 (1952) 74-84
15. McCutcheon A.R., et al. Antiviral screening of British Columbian medicinal plants. J. Ethnopharmacol. 49 (1995) 101-110
16. Chamorro C., et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit. Care Med. 24 (1996) 932-939
17. Chamorro G., et al. Pharmacology and toxicology of Spirulina alga. Rev. Invest. Clin. 48 (1996) 389-399
18. De Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. 10 (2000) 255-277
19. Schaeffer D.J., and Krylov V.S. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol. Environ. Safety 45: (2000) 208-227
20. McManus N.H. Microtiter assay for interferon: microspectrophotometric quantitation of cytopathic effect. Appl. Environ. Microbiol. 31 (1976) 35-38
21. Sudo K., et al. A sensitive assay system screening antiviral compounds against herpes simplex virus type 1 and type 2. J. Virol. Methods 49 (1994) 169-178
22. Takeuchi H., et al. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J. Virol. Methods 33 (1991) 61-71
23. 50-values and cell survival. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 813-823
24. Vanden Berghe D.A.R., et al. Antiviral agents from higher plants and an example of structure-activity relationship of 3-methoxyflavones. In: Colegate S.M., and Milyneux R.J. (Eds). Bioactive Natural Products: Detection, Isolation, and Structural Determination (1993), CRC Press 405-440
25. Vlietinck A.J., et al. Plant substances as antiviral agents. Curr. Org. Chem. 1 (1997) 307-344
26. Apers S., et al. Antiviral activity of simalikalactone D, a quassinoid from Quassia africana. Planta Med. 68 (2002) 20-24
27. Hsiang C.Y., et al. Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication. Am. J. Chin. Med. 29 (2001) 459-467
28. Kimura H., et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J. Clin. Microbiol. 37 (1999) 132-136
29. Laue T., et al. Detection of dengue virus RNA inpatients after primary or secondary dengue infection by using the TaqMan automated amplification system. J. Clin. Microbiol. 37 (1999) 2543-2547
30. Tanaka N., et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J. Med. Virol. 60 (2000) 455-462
31. Josefsson A., et al. Detection and quantification of human papillomavirus by using the fluorescent 59 exonuclease assay. J. Clin. Microbiol. 37 (1999) 490-496
32. Locatelli G., et al. Real-time quantitative PCR for human herpesvirus 6 DNA. J. Clin. Microbiol. 38 (2000) 4042-4048
33. Loeb K., et al. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 32 (2000) 626-629
34. Schutten M., et al. Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J. Virol. Methods 88 (2000) 81-87
35. Sells M.A., et al. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 1005-1009
36. Zhou Z., et al. Prodocutechnic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo. Antivir. Res. 74 (2007) 59-64
37. Korba B.E., et al. Hepatocellular carcinoma in woodduck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 9 (1989) 461-470
38. Shin M.S., et al. A flavonid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antivir. Res. 67 (2005) 163-168
39. Zhang Y., et al. Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-carbohydrate complex from Prunella vulgaris. Antivir. Res. 75 (2007) 242-249
40. Yim K.C., et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J. Virol. 79 (2005) 14632-14639
41. Gordon Y.J., et al. A fast, simple reactivation method for the study of HSV-1 latency in the rabbit ocular model. Investig. Ophthalmol. Vis. Sci. 31 (1990) 921-924
42. Gordon Y.J., et al. The development of an improved reactivation model for the study of HSV-1 latency. Invest. Ophthalmol. Vis. Sci. 27 (1986) 1230
43. Gordon Y.J., et al. The role of herpesvirus type 1 thymidine kinase in experimental ocular infections. Am. J. Ophthalmol. 95 (1983) 175
44. Collins P.L., et al. Respiratory syncytial virus. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields Virology. 3rd ed. (1996), Lippincott-Raven Publishers 1313-1351
45. Glezen W.P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140 (1986) 543-546
46. Kim H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
47. Graham B.S., et al. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26 (1988) 153-162
48. Kao Y.J., et al. Induction and regulation of nitric oxide synthase in airway epithelial cells by respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 163 (2001) 532-539
49. Trifilieff A., et al. Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression. J. Immunol. 165 (2000) 1526-1533
50. Belshe R.B., et al. Experimental respiratory syncytial virus infection of four species of primates. J. Med. Virol. 1 (1977) 157-162
51. Crowe Jr. J.E., et al. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J. Infect. Dis. 173 (1996) 829-839
52. Richardson L.S., et al. Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness. J. Med. Virol. 3 (1978) 91-100
53. Prince G.A., et al. Respiratory syncytial virus infection in inbred mice. Infect. Immun. 26 (1979) 764-766
54. Prince G.A., et al. Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants. Infect. Immun. 26 (1979) 1009-1013
55. Kakuk T.J., et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with 1368 Byrd and Prince CID; 25 (December) a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J. Infect. Dis. 167 (1997; 1993) 553-561
56. Simoes E.A. Natural and Vaccine Induced Immunity to RSV in Primates. NIH Publication No R01 AI37271-02 (1995), National Institutes of Health
57. Hildreth S.W., et al. A parenterally administered subunit RSV vaccine: safety studies in animals and adult humans. Pediatr. Res. 25 (1989) 180A
58. Prince G.A., et al. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am. J. Pathol. 93 (1978) 771-791
59. Prince G.A., and Porter D.D. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J. Infect. Dis. 173 (1996) 598-608
60. Van der Poel W.H.M., et al. Respiratory syncytial virus infections in human beings and in cattle. J. Infect. 29 (1994) 215-228
61. Belknap E.B., et al. Experimental respiratory syncytial virus infection in calves and lambs. J. Vet. Diagn. Invest. 7 (1995) 285-298
62. Baker J.C. The characteristics of respiratory syncytial viruses. Vet. Med. (Praha) 88 (1993) 1190-1195
63. Viuff B., et al. Sites of replication of bovine respiratory syncytial virus in naturally infected calves as determined by in situ hybridisation. Vet. Pathol. (1996) 383-390
64. Wright P.F., et al. Temperature-sensitive mutants of respiratory syncytial virus: in vivo studies in hamsters. J. Infect. Dis. 122 (1970) 501-512
65. Coates H.V., and Chanock R.M. Experimental infection with respiratory syncytial virus in several species of animals. Am. J. Hyg. 76 (1962) 302-312
66. Openshaw P.J.M. Immunopathological mechanisms in respiratory syncytial virus disease. Springer Semin. Immunopathol. 17 (1995) 187-201
67. Graham B.S. Immunological determinants of disease caused by respiratory syncytial virus. Trends Microbiol. 4 (1996) 290-294
68. Prince G.A., and Porter D.D. The pathogenesis of respiratory syncytial virus infection in infant ferrets. Am. J. Pathol. 82 (1976) 339-352
69. Droebner K., et al. CYSTUS052, a polyphenol rich plant extract, exerts anti influenza virus activity in mice. Antivir. Res. 76 (2007) 1-10
70. World Health Organisation. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory Techniques in Rabies. 4th ed. (1996), WHO
71. Baer G.M. The Natural History of Rabies. 2nd ed. (1991), CRC Press p. 620
72. Bourhy H., and Kissi Band Tordo N. Molecular diversity of the lyssavirus genus. Virology 194 (1993) 70-81
73. Fekadu M., et al. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies virus and rabies-related viruses. Vaccine 6 (1988) 533-539
74. Reid J.E., and Jackson A.C. Experimental rabies virus infection in Artibeus jamaicensis bats with CVS-24 variants. J. NeuroVirol. 7 (2001) 511-517
75. Rudd R.J., and Trimachi C.V. Comparison of sensitivity of BHK-21 and murine neuroblastoma cells in the isolation of a street strain rabies virus. J. Clin. Microbiol. 25 (1987) 145-168
76. Barrat J., et al. Diagnostic de la rage sur culture cellulaire, comparaison des résultats de l'inoculation au neuroblastome murin et de l'inoculation à la souris. Comp. Immunol. Microbiol. Infect. Dis. 11 (1986) 207-214
77. Chávez J.H., et al. Evaluation of antiviral activity of phenolic compounds and derivatives against rabies virus. Vet. Microbiol. 116 (2006) 53-59
78. Goffinet C., et al. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. PNAS 104 (2007) 1015-1020
79. Keppler O.T., et al. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J. Exp. Med. 195 (2002) 719-736
80. Keppler O.T., et al. Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J. Virol. 75 (2001) 8063-8073
81. Goffinet C., and Keppler O.T. Efficient non-viral gene delivery into primary lymphocytes from mice and rats. FASEB J. 20 (2006) 500-502
82. Keppler O.T., et al. Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J. Virol. 79 (2005) 1655-1665
83. Li Y., et al. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65 (1991) 3973-3985
84. He J., et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385 (1997) 645-649
85. Reuter S., et al. Role of HIV-2 envelope in Lv2-mediated restriction. Virology 332 (2005) 347-358
86. Venzke S., et al. Expression of Nef proteins downregulates CXCR4, the major HIV-1 coreceptor, from the cell surface and thereby enhances resistance to superinfection. J. Virol. 80 (2006) 11141-11152
87. Cavrois M., et al. Nat. Biotechnol. 20 (2002) 1151-1154
88. Van Maele B., et al. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J. Virol. 77 (2003) 4685-4694
89. Brussel A., et al. Longitudinal monitoring of 2 long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 17 (2003) 645-652
90. Gitilin N. Hepatitis B: diagnosis, prevention and treatment. Clin. Chem. 43 (1997) 1500-1506
91. Park N.H., et al. Chronic hepatitis B in hepatocarcinogenesis. Postgrad. Med. 82 (2006) 507-515
92. Huang R.L., et al. Anti-hepatitis B virus effects of wogonin isolated from Scutellaria baicalensis. Planta Med. 66 (2000) 694-698
93. Gish R.G. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin. Liver Dis. 9 (2005) 541-565
94. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25 Suppl. 1 (2005) 3-8
95. Perrillo R.P. Current treatment of chronic hepatitis B: benefits and limitations. Semin. Liver Dis. 25 Suppl. 1 (2005) 20-28
96. Guo Q.L., et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antivir. Res. 74 (2007) 16-24
97. Guidotti L.G., et al. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69 (1995) 6158-6169
98. Jibert A.R., et al. Rapid resolution of duck hepatits B virus infections occurs after massive hepatocellular. J. Virol. 66 (1992) 1377-1388
99. Yao Y., et al. Study on the replication of hepatitis B virus compared with that of duck hepatitis B virus in primary duck hepatocytes. Zhonghua Yi Xue Za Zhi 81 (2001) 1157-1161
100. Freiman J.S., et al. Experimental duck hepatitis B virus infection: pathology and evolution of hepatic and extrahepatic infection. Hepatology 8 (1988) 507-513
101. Guiver M., et al. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 71 (2001) 1609-1615
102. Lallemand F., et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J. Clin. Microbiol. 38 (2000) 1404-1408
103. Hussein G., et al. Inhibitory effects of Sudanese plant extracts on HIV-1 replication and HIV-1 protease. Phytother. Res. 13 (1999) 31-36
104. Premanathan M., et al. Antiviral properties of a mangrove plant, Rhizophora apiculata Blume, against human immunodeficiency virus. Antivir. Res. 44 (1999) 113-122
105. Premanathan M., et al. In vitro anti-human immunodeficiency virus activity of polysaccharide from Rhizophora mucronata Poir. Biosci. Biotechnol. Biochem. 63 (1999) 1187-1191
106. Calabrese C., et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother. Res. 14 (2000) 333-338 PMID: 10925397
107. Asres K., et al. Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. Phytother. Res. 15 (2001) 62-69
108. Chan P.K., et al. Survey for the presence and distribution of human herpesvirus 8 in healthy brain. J. Clin. Microbiol. 38 (2000) 2772-2773 109
109. Chattopadhyay D., et al. Dose dependent therapeutic antiinfectives from ethnomedicines of Bay Islands. Chemotherapy 52 (2006) 151-157
110. Flint S.J., et al. Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses. 2nd ed. (2004), ASM Press
111. Mukhtar M., et al. Antiviral potentials of medicinal plants. Virus Research 131 2 (2008) 111-120
112. Tolo F.M., et al. Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus. J. Ethnopharmacol. 104 (2006) 92-99
113. Yang Chien-Min, et al. The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-β-d-glucose isolated from Phyllanthus urinaria against herpes simplex virus type 1 and type 2 infection. J. Ethnopharmacol. 110 (2007) 555-558
114. Serkedjieva J., et al. Protective efficacy of an aerosol preparation, obtained from Geranium sanguineum L., in experimental influenza infection. Pharmazie 63 (2008) 160-163
115. Pantev A., et al. Biologically active constituents of a polyphenol extract from Geranium sanguineum L. with anti-influenza activity. Z. Naturforsch. [C] 61 (2006) 508-516
116. Serkedjieva J. Antiinfective activity of a plant preparation from Geranium sanguineum L. Pharmazie 52 (1997) 799-802
117. Zakay-Rones Z., et al. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J. Int. Med. Res. 32 (2004) 132-140
118. Huang K.L., et al. Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells. World J. Gastroenterol. 12 35 (2006) 5721-5725
119. Chang J.S., et al. Ethanol extract of Polygonum cuspidatum inhibits hepatitis B virus in a stable HBV-producing cell line. Antivir. Res. 66 (2005) 29-34
120. Zuo G.Y., et al. In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds. Antivir. Chem. Chemother. 16 (2005) 393-398
121. DeFelipe A.M., et al. Antiviral effect of guazuma ulmifolia and stryphnodendron adstringens on poliovirus and bovine herpesvirus. Biol. Pharm. Bull. 29 (2006) 1092-1095
122. Micol V., et al. The olive leaf extract exhibits antiviral activity against viral haemorrhagic septicaemia rhabdovirus (VHSV). Antivir. Res. 66 (2005) 129-136
123. Li S.Y., et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antivir. Res. 67 (2005) 18-23
124. Notka F., et al. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antivir. Res. 64 (2004) 93-102
125. Lee-Huang S., et al. Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment. Biochem. Biophys. Res. Commun. 307 (2003) 1029-1037
126. Cella M., et al. Virucidal activity presence in Trichilia glabra leaves. Rev. Argent. Microbiol. 36 (2004) 136-138
127. Yamai M., et al. Antiviral activity of a hot water extract of black soybean against a human respiratory illness virus. Biosci. Biotechnol. Biochem. 67 (2003) 1071-1079
128. Parida M.M., et al. Inhibitory potential of neem (Azadirachta indica Juss.) leaves on dengue virus type-2 replication. J. Ethnopharmacol. 79 (2002) 273-278